In ERα-positive/HER 2-positive breast cancers, where AR is expressed in more than 60% of cases [6], studies have suggested that AR positivity is responsible for smaller tumor sizes, lower Ki67 percentages, and less aggressive phenotypes [35]. The gene discussed is ESR1; the disease is neoplasm.